COVID-2019 Alert

The latest information about the 2019 Novel Coronavirus, including vaccine clinics for children ages 5 years old and older.

La información más reciente sobre el nuevo Coronavirus de 2019, incluidas las clínicas de vacunación para niños de 5 años en adelante.


Immunotherapy Treatment Options

KYMRIAH now available

Lucile Packard Children’s Hospital Stanford is one of a select group of certified treatment centers offering the FDA-approved CAR T-cell therapy KYMRIAH. This treatment is available to patients up to 26 years of age who have acute lymphoblastic leukemia (ALL) that either relapsed (came back after going into remission) or never went into remission after other leukemia treatments were used (refractory). You and your care team will decide if KYMRIAH is right for your child.

As one of the centers involved in the early clinical trials of KYMRIAH, we have significant experience caring for patients who are receiving CAR T-cell therapy, from addressing potential side effects to providing long-term follow-up care.

Immunotherapy clinical trials

KYMRIAH was made possible by years of testing in clinical trials. Our researchers and physicians are continuing to test ways for making immunotherapy more successful and expanding it to treat other types of cancers beyond leukemia.

Immunotherapy clinical trials currently enrolling at Stanford Children’s Health include the following:

    • CD19/CD22: A first-in-human trial using a CAR T cell to target two different surface proteins at once to stop the cancer from having time to adapt and evade the immune system. This trial is for patients with recurrent or refractory acute lymphoblastic leukemia. We are the only children’s hospital in California to offer this kind of trial.
    • CD22: An only-at-Stanford trial to study the efficacy of CAR T cells targeting CD22 alone for children and young adults with relapsed B-cell malignancies.
    • GD2: A first-in-human trial evaluating whether GD2 CAR T cells are safe and can effectively fight against diffuse intrinsic pontine glioma (DIPG), a type of brain tumor, and spinal diffuse midline glioma (DMG), a spine tumor. This trial is available only at Stanford.

    Our researchers are working to apply immunotherapy to other types of cancer, including solid tumors such as osteosarcoma, Ewing sarcoma, and medulloblastoma, and other types of brain tumors.

    Stanford Cancer Institute logo